-
Patient Rating
4.9 /5( out of 21 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety.
Patients are de-identified for confidentiality and patient privacy.June 13, 2024HUNTSMAN CANCER CENTERDr Patel has treated us as famlly over these past 8 years.
June 05, 2024HUNTSMAN CANCER CENTERHe's team is great
May 23, 2024HUNTSMAN CANCER CENTERDr. Patel was straight forward with his recommendations and answered honestly our questions. We left with hope in our hearts.
March 13, 2024HUNTSMAN CANCER CENTERDr. Shiven Patel is very attentive, knowledgeable and encouraging. He takes time to explain and to ask about and respond to my concerns. I never feel that it is a rushed appointment. I appreciate his trust in me as well. I also enjoy his sense of humor.
January 30, 2024HUNTSMAN CANCER CENTERAbsolutely the best care from entire staff and hospital itself (including infusion centers)
November 29, 2023HUNTSMAN CANCER CENTERHe takes time to listen to our concerns, answers all questions so we understand him, and he is frank and honest with information. Excellent bedside manner, as does his nurse, Heaven!
November 16, 2023HUNTSMAN CANCER CENTERHe was knowledgeable, confident and reassuring.
October 11, 2023HUNTSMAN CANCER CENTERDr. Patel has been my oncologist for 5 years. He respects my opinions and always gets my input on his choices for treatment. I would say he has done very well with my treatment. I am in my sixth year with stage 4 lung cancer and still leading a quite normal life I have no pain,but I get tired easily. I still can do all my usual activities. I could not ask for anything better.
July 17, 2023HUNTSMAN CANCER CENTERAlways good
-
News & Podcasts
Huntsman Cancer Institute News
-
Clinical Trials
- Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
- Phase II, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
- Phase II, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
- Phase II, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
- Phase II, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
- Phase II, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
- Phase II, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
- Phase II, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
- First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
- Beamion LUNG-2: A Phase III, Open-Label, Randomized, Activecontrolled, Multi-Centre Trial Evaluating Orally Administered BI 1810631 Compared with Standard of Care As First-Line Treatment in Patients with Unresectable, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations
- Randomized Phase II Study of Capmatinib Plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
- Randomized Phase II Study of Capmatinib Plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
- Randomized Phase II Study of Capmatinib Plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
- Randomized Phase II Study of Capmatinib Plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
( out of 21 reviews )
